Ortho Pharmaceuticals Report issue

For profit Phase 3
Founded: Raritan NJ United States (1931)
Status: Acquired by Johnson and Johnson (1993)

Organization Overview

First Clinical Trial
1999
NCT00002072
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2002

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

epoetin (Epogen) (7 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Gastrointestinal Neoplasms (Phase 3)

Rectal Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 1